Literature DB >> 17051438

Networks and hubs for the transcriptional control of osteoblastogenesis.

Jane B Lian1, Gary S Stein, Amjad Javed, Andre J van Wijnen, Janet L Stein, Martin Montecino, Mohammad Q Hassan, Tripti Gaur, Christopher J Lengner, Daniel W Young.   

Abstract

We present an overview of the concepts of tissue-specific transcriptional control mechanisms essential for development of the bone cell phenotype. BMP2 induced transcription factors constitute a network of activities and molecular switches for bone development and osteoblast differentiation. Among these regulators are Runx2 (Cbfa1/AML3), the principal osteogenic master gene for bone formation, as well as homeodomain proteins and osterix. Runx2 has multiple regulatory activities, including activation or repression of gene expression, and integration of biological signals from developmental cues, such as BMP/TGFbeta, Wnt and Src signaling pathways. Runx2 provides a new paradigm for transcriptional control by functioning as a principal scaffolding protein in nuclear microenvironments to control gene expression in response to physiologic signals (growth factors, cytokines and hormones). The protein serves as a hub for the coordination of activities essential for the expansion and differentiation of osteogenic lineage cells through the formation of co-regulatory protein complexes organized in subnuclear domains. Mechanisms by which Runx2 supports commitment to osteogenesis and determines cell fate involve its retention on mitotic chromosomes. Disruption of a unique protein module, the subnuclear targeting signal of Runx2, has profound effects on osteoblast differentiation and metastasis of cancer cells in the bone microenvironment. Runx2 target genes include regulators of cell growth control, components of the bone extracellular matrix, angiogenesis, and signaling proteins for development of the osteoblast phenotype and bone turnover. The specificity of Runx2 regulatory activities provides a basis for novel therapeutic strategies to correct bone disorders.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17051438     DOI: 10.1007/s11154-006-9001-5

Source DB:  PubMed          Journal:  Rev Endocr Metab Disord        ISSN: 1389-9155            Impact factor:   6.514


  181 in total

Review 1.  Role of covalent modifications of histones in regulating gene expression.

Authors:  V A Spencer; J R Davie
Journal:  Gene       Date:  1999-11-15       Impact factor: 3.688

2.  Smad6 interacts with Runx2 and mediates Smad ubiquitin regulatory factor 1-induced Runx2 degradation.

Authors:  Run Shen; Mo Chen; Yong-Jun Wang; Hiroyuki Kaneki; Lianping Xing; Regis J O'keefe; Di Chen
Journal:  J Biol Chem       Date:  2005-11-18       Impact factor: 5.157

3.  Repression of Runx2 function by TGF-beta through recruitment of class II histone deacetylases by Smad3.

Authors:  Jong Seok Kang; Tamara Alliston; Rachel Delston; Rik Derynck
Journal:  EMBO J       Date:  2005-06-30       Impact factor: 11.598

4.  Both the Smad and p38 MAPK pathways play a crucial role in Runx2 expression following induction by transforming growth factor-beta and bone morphogenetic protein.

Authors:  Kyeong-Sook Lee; Seung-Hyun Hong; Suk-Chul Bae
Journal:  Oncogene       Date:  2002-10-17       Impact factor: 9.867

5.  Runx1/AML1/Cbfa2 mediates onset of mesenchymal cell differentiation toward chondrogenesis.

Authors:  YongJun Wang; Ruth M Belflower; Yu-Feng Dong; Edward M Schwarz; Regis J O'Keefe; Hicham Drissi
Journal:  J Bone Miner Res       Date:  2005-05-23       Impact factor: 6.741

6.  Histone deacetylase 3 interacts with runx2 to repress the osteocalcin promoter and regulate osteoblast differentiation.

Authors:  Tania M Schroeder; Rachel A Kahler; Xiaodong Li; Jennifer J Westendorf
Journal:  J Biol Chem       Date:  2004-08-02       Impact factor: 5.157

7.  Cbfa1/RUNX2 directs specific expression of the sclerosteosis gene (SOST).

Authors:  Brad Sevetson; Scott Taylor; Yang Pan
Journal:  J Biol Chem       Date:  2004-01-22       Impact factor: 5.157

8.  Homeobox protein MSX2 acts as a molecular defense mechanism for preventing ossification in ligament fibroblasts.

Authors:  Tatsuya Yoshizawa; Fumio Takizawa; Futabako Iizawa; Osamu Ishibashi; Hiroyuki Kawashima; Akio Matsuda; Naoto Endo; Hiroyuki Kawashima
Journal:  Mol Cell Biol       Date:  2004-04       Impact factor: 4.272

9.  Proteasomal degradation of Runx2 shortens parathyroid hormone-induced anti-apoptotic signaling in osteoblasts. A putative explanation for why intermittent administration is needed for bone anabolism.

Authors:  Teresita Bellido; A Afshan Ali; Lilian I Plotkin; Qiang Fu; Igor Gubrij; Paula K Roberson; Robert S Weinstein; Charles A O'Brien; Stavros C Manolagas; Robert L Jilka
Journal:  J Biol Chem       Date:  2003-10-01       Impact factor: 5.157

Review 10.  Skeletons in the p53 tumor suppressor closet: genetic evidence that p53 blocks bone differentiation and development.

Authors:  Gerard P Zambetti; Edwin M Horwitz; Ernestina Schipani
Journal:  J Cell Biol       Date:  2006-03-13       Impact factor: 10.539

View more
  187 in total

1.  Congenic mice provide in vivo evidence for a genetic locus that modulates intrinsic transforming growth factor β1-mediated signaling and bone acquisition.

Authors:  Aditi Mukherjee; Emily A Larson; Amy S Carlos; John K Belknap; Peter Rotwein; Robert F Klein
Journal:  J Bone Miner Res       Date:  2012-06       Impact factor: 6.741

Review 2.  MicroRNA control of bone formation and homeostasis.

Authors:  Jane B Lian; Gary S Stein; Andre J van Wijnen; Janet L Stein; Mohammad Q Hassan; Tripti Gaur; Ying Zhang
Journal:  Nat Rev Endocrinol       Date:  2012-01-31       Impact factor: 43.330

3.  miRNA-34c regulates Notch signaling during bone development.

Authors:  Yangjin Bae; Tao Yang; Huan-Chang Zeng; Philippe M Campeau; Yuqing Chen; Terry Bertin; Brian C Dawson; Elda Munivez; Jianning Tao; Brendan H Lee
Journal:  Hum Mol Genet       Date:  2012-04-12       Impact factor: 6.150

Review 4.  Inflammatory bone loss: pathogenesis and therapeutic intervention.

Authors:  Kurt Redlich; Josef S Smolen
Journal:  Nat Rev Drug Discov       Date:  2012-03-01       Impact factor: 84.694

5.  Distinct functions of Sox2 control self-renewal and differentiation in the osteoblast lineage.

Authors:  Eunjeong Seo; Upal Basu-Roy; Jiri Zavadil; Claudio Basilico; Alka Mansukhani
Journal:  Mol Cell Biol       Date:  2011-09-19       Impact factor: 4.272

6.  Pbx1 represses osteoblastogenesis by blocking Hoxa10-mediated recruitment of chromatin remodeling factors.

Authors:  Jonathan A R Gordon; Mohammad Q Hassan; Sharanjot Saini; Martin Montecino; Andre J van Wijnen; Gary S Stein; Janet L Stein; Jane B Lian
Journal:  Mol Cell Biol       Date:  2010-05-03       Impact factor: 4.272

7.  Histone demethylases KDM4B and KDM6B promotes osteogenic differentiation of human MSCs.

Authors:  Ling Ye; Zhipeng Fan; Bo Yu; Jia Chang; Khalid Al Hezaimi; Xuedong Zhou; No-Hee Park; Cun-Yu Wang
Journal:  Cell Stem Cell       Date:  2012-07-06       Impact factor: 24.633

Review 8.  The role of NELL-1, a growth factor associated with craniosynostosis, in promoting bone regeneration.

Authors:  X Zhang; J Zara; R K Siu; K Ting; C Soo
Journal:  J Dent Res       Date:  2010-07-20       Impact factor: 6.116

9.  Genetic Engineering of Mesenchymal Stem Cells for Differential Matrix Deposition on 3D Woven Scaffolds.

Authors:  Nguyen P T Huynh; Jonathan M Brunger; Catherine C Gloss; Franklin T Moutos; Charles A Gersbach; Farshid Guilak
Journal:  Tissue Eng Part A       Date:  2018-07-13       Impact factor: 3.845

Review 10.  Osteoblast dysfunctions in bone diseases: from cellular and molecular mechanisms to therapeutic strategies.

Authors:  Pierre J Marie
Journal:  Cell Mol Life Sci       Date:  2014-12-09       Impact factor: 9.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.